Segra enters into Strategic Plant Genotyping and Tissue Culture Agreement with Sugarbud
December 05 2019 - 4:57PM
Segra International Corp. ("
Segra") is pleased to
announce that it has entered into a strategic plant genotyping and
tissue culture agreement with Sugarbud Craft Growers Corp. (TSXV:
SUGR, SUGR.WT, SUGR.RT) ("
Sugarbud") through
its wholly owned subsidiary Segra Biogenesis Corp.
Under the terms of the agreement, which includes
royalties tied to production success, Segra will provide Sugarbud
with exclusive and proprietary cannabis cultivars as well as tissue
culture technology and services for the preservation, regeneration,
and production of key cultivars already held by Sugarbud.
Plant tissue culture, also known as plant micropropagation, is an
advanced scientific technique utilized in many commercial
agricultural applications to mass-produce plants with desirable
traits. Using micropropagation, large volumes of sterile, healthy,
disease-free, and genetically identical plantlets can be rapidly
produced. Plant tissue culture eliminates systemic diseases in
starting materials that can negatively impact yields and chemotype
expression, while at the same time dramatically reducing the space
required to maintain viable stock plants and produce healthy and
uniform plants year-round.
"The genetic diversity, reliability and
integrity of our cultivars is one of the cornerstones of our
high-quality premium cannabis value proposition and our product
leadership strategy," stated Sugarbud CEO, John Kondrosky. "We
believe that a reliable customer experience from batch-to-batch is
an essential part of maintaining consumer confidence and trust in
our brand."
"Sugarbud is committed to quality and we are
very excited to be partnering with Segra to ensure the quality and
integrity of our cultivars. The benefits of tissue culture for the
cannabis industry and consumers alike are significant and we look
forward to collaborating closely with Segra to ensure that our
customers experience only high-quality premium cannabis," continued
Mr. Kondrosky.
"The words premium and quality are thrown around
often in this industry, however Sugarbud's early adoption of tissue
culture proves they are taking the necessary steps to ensure
quality at the highest level," stated Segra CEO, Todd McMurray. "It
Is this level of dedication and commitment to quality that builds
lasting brands."
About Segra
Segra is an agriculture technology company
offering innovative services that accelerate the advancement of the
cannabis industry to better serve society. The company’s plant
tissue culture and genomics technologies, coupled with a vast
business ecosystem, empower its clients to drive financial
performance and mitigate risk, while exploring the next frontiers
of optimized cultivation practices for the rapidly evolving
medical, recreational, and hemp markets. Segra is developing
industrial-scale facilities to produce disease-free, robust, and
DNA fingerprinted cannabis plantlets for licensed producers
globally. To support this vision, Segra has assembled a world-class
team of specialists in the fields of agronomy, molecular genetics,
plant tissue culture, and regulatory compliance. Segra currently
has agreements with many leading global cannabis producers,
including the Canadian licensed producers HEXO Corp., Agripharm
Corp., and The Supreme Cannabis Company Inc.
https://www.segra-intl.com/
About Sugarbud
Sugarbud is a federally licensed Alberta-based
publicly traded cannabis company focused on the cultivation and
production of high-quality premium cannabis, and product leadership
through the development, production and distribution of value-added
cannabis products in Canada.
http://www.sugarbud.ca/
Contact Information: Segra International Corp.
E-mail: carson.otto@segra-intl.com |
|
Website:
http://www.segra-intl.com/
Forward-looking information
This news release includes statements containing
certain “forward-looking information” within the meaning of
applicable securities law (“forward-looking statements”).
Forward-looking statements are frequently characterized by words
such as “plan”, “continue”, “expect”, “project”, “intend”,
“believe”, “anticipate”, “estimate”, “may”, “will”, “potential”,
“proposed” and other similar words, or statements that certain
events or conditions “may” or “will” occur. These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
Sucro (TSXV:SUGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucro (TSXV:SUGR)
Historical Stock Chart
From Sep 2023 to Sep 2024